Background-The treatment of recurrent pleural effusion in advanced malignant disease should be efficient and with tolerable side effects. Since 1983 intrathoracic instillation of the antimalaria drug mepacrine has been used to achieve pleurodesis. The cytotoxic drug bleomycin has been claimed to be equally effective and with fewer side effects. The present study was designed to compare these two agents. Methods-Forty patients with carcinoma and pleural effusions refractory to repeated pleural aspirations over the previous 12 weeks were randomised to receive treatment with intrathoracic instillation of mepacrine or bleomycin. Fluid volumes before and after pleurodesis, drainage time, and side effects were registered and analysed, and the response to treatment was evaluated by clinical examination and chest radiography.
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Background-The treatment of recurrent pleural effusion in advanced malignant disease should be efficient and with tolerable side effects. Since 1983 intrathoracic instillation of the antimalaria drug mepacrine has been used to achieve pleurodesis. The cytotoxic drug bleomycin has been claimed to be equally effective and with fewer side effects. The present study was designed to compare these two agents. Methods-Forty patients with carcinoma and pleural effusions refractory to repeated pleural aspirations over the previous 12 weeks were randomised to receive treatment with intrathoracic instillation of mepacrine or bleomycin. Fluid volumes before and after pleurodesis, drainage time, and side effects were registered and analysed, and the response to treatment was evaluated by clinical examination and chest radiography. Results-The amount of fluid produced after treatment in the patients receiving mepacrine was lower than in those receiving bleomycin, and the duration of chest drainage was shorter. After 30 days 16 Positive cytology 4 6 Positive pleural biopsy 4 2 Negative cytology or biopsy 2 4 Pleural fluid not examined 10 8 Department maintained until fluid production was reduced to about 100 ml/day and chest radiographs showed a dry pleural cavity. Only two patients were included in the study with fluid production greater than 100 ml/day (320 and 355 ml/day). The tube was clamped close to the thoracic wall and the sclerosing agent was injected through a small cannula directly into the tube. We used 800 mg mepacrine diluted in 20 ml saline or 60 mg bleomycin in 100 ml saline. The patients were then turned from side to side for two hours to ensure optimal exposure of the substance to all parts of the pleural space. In the mepacrine group suction was re-established after two hours according to our hospital protocol, while in the bleomycin group suction was re-established the next day according to the procedure of Paladine and coworkers. 5 Following the instillation fluid production initially increased as a result of the inflammatory response. The chest tube was removed when it had reduced to 100 ml/day or less. Patients with sustained volumes of more than 200 ml/day after the pleurodesis were considered to be primary therapy failures. These patients were offered treatment with the alternative agent. Possible effects of the second instillation were not evaluated.
The patients were followed up with chest radiographs monthly for three months. The response was classified as: (1) no reaccumulation of fluid; (2) small amounts of fluid reaccumulation with no or mild symptoms; and (3) reaccumulation of fluid with severe dyspnoea needing thoracocentesis (failure).
STATISTICAL ANALYSIS
The Mann-Whitney rank sum test was used for comparison of the continual variables in 
Results
The numbers in each histological group were small and the patients with mesothelioma and bronchial carcinoma were particularly unevenly distributed. The time between diagnosis of the effusion and the pleurodesis was the same in both groups, and there were no significant differences in the number of thoracocenteses, the duration of drainage, or the volumes of fluid drained before the pleurodesis. After pleurodesis the median drainage time was significantly longer in the bleomycin group, and the total amount of drained fluid was more than four times higher than in the mepacrine group (table 3) .
Primary therapy failure occurred in four cases in the bleomycin group (two breast cancer, one ovarian cancer, one non-Hodgkin's lymphoma). All these patients responded well to a second treatment with mepacrine, although they were evaluated as failure after 30 days according to the protocol. In one patient with oesophageal carcinoma the effusion was resistant to treatment with both agents and drainage was maintained until death 21 
Discussion
The prognosis for patients with malignant pleural effusion is very poor, with only 10-15% being alive after one year,9 and is probably best in breast cancer and bronchial carcinoma.9 Our patients came to pleurodesis a median 2-3 months after the diagnosis of pleural effusion (table 2) . This rather long time might explain some of the short survival times after pleurodesis. Such 13 and a 50% response to bleomycin, which was lower than that reported by others. '3 The two methods we used for intracavitary treatment were not entirely the same as the drain clamping time was two hours after mepacrine and 24 hours after bleomycin, and the solution volumes were 20 and 100 ml, respectively. This could have influenced the results but, if drainage time is calculated from the end of the clamping period, the difference in volumes drained is still significant but the difference in drainage time is not.
Instillation of sclerosing agents into the pleural cavity has been associated with numerous, and often serious, side effects.'4 In our study the side effects were moderate with no statistical difference between the two agents. According to Bayly and coworkers fever was more common with mepacrine than with tetracycline,'2 whereas the pyrogenic effect of bleomycin was similar to that of tetracycline in another randomised trial."I In our study mepacrine seemed less toxic than previously reported,' including a moderate fever of short duration and moderate chest pain the day after the instillation. Fever was more common with bleomycin in our study than described elsewhere.45
Serious toxic effects were not seen in our study, although two 
